Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. by Starzynska, T. et al.
Br. J. Cancer (1992), 66, 558-562
© Macmillan Press Ltd., 1992
Prognostic significance of p53 overexpression in gastric and colorectal
carcinoma
T. Starzynskal, M. Bromley2, A. Ghosh3 & P.L. Stern3
iDepartment ofGastroenterology, Medical Pomeranian Academy, Unii Lubelskieji, 71-344 Szczecin, Poland; and Cancer
Research Campaign Departments of 2Histology and 3Immunology, Paterson Institutefor Cancer Research, Christie Hospital,
NHS Trust, Manchester M20 9BX, UK.
Summary p53 expression was examined in 55 gastric and 107 colorectal carcinomas with an immunoperox-
idase technique, using the polyclonal antibody CM1 on routinely fixed, paraffin embedded tissue. p53 protein
was detected in 47% gastric and in 46% colorectal carcinomas and found to correlate with stage of disease
and unfavourable clinical outcome (P<0.001). Thus, the proportion of positively reacting neoplasms in-
creased as the stage progressed, tumours which had invaded regional lymph-nodes overexpressed p53 more
frequently than localised carcinomas and an elevated level of p53 was associated with early relapse and death.
In colorectal carcinoma p53 positivity was also linked with site and macroscopic configuration of the primary
tumour and was most frequently expressed in carcinomas from the rectum and in ulcerative tumours. p53
overexpression was irrrespective of tumour grade. Uniform negative reactivity with anti-p53 antibody was seen
in normal epithelium adjacent to carcinoma, intestinal metaplasia, atrophic gastritis and in colonic adenomas.
There was a good correlation between immunohistochemical staining on paraffin and frozen sections. These
studies suggest that in gastric and colorectal carcinoma, immunohistochemical detection of p53 protein in
routinely fixed tissue can be used along with other established parameters to assess prognostic outcome,
especially to identify patients with poor short-term prognosis.
The p53 gene mapped on chromosome 17p is an important
negative regulator of normal cell growth and division (Finlay
et al., 1989; Chen et al., 1990; Diller et al., 1990; Isaacs et at.,
1991). Alteration or inactivation of p53 by mutation can
allow a cell to escape from normal into uncontrolled growth
leading to cancer development. p53 mutations are a very
common genetic change in a variety of human tumours
(Baker et al., 1989; Takahashi et al., 1989; Nigro et al., 1989;
Bartek et al., 1990a; Marks et al., 1991; Tamura et al., 1991).
The majority of the mutations alter the conformation of the
nuclear protein product, encoded by the p53 gene (Gannon
et al., 1990; Bartek et al., 1990b; Rodrigues et al., 1990). In
normal cells and tissues the p53 protein has a very short
half-life (Oren et al., 1981) and attains such a low level that it
is not detectable histologically (Gannon et al., 1990). The
mutant forms have an extended half-life (Finlay et al., 1988)
and being overexpressed are readily detected by immunohis-
tochemistry. Elevated p53 levels have been described in
different human neoplasms (Crawford et al., 1984; Cattoretti
et al., 1988; Bartek et al., 1990a; Iggo et al., 1990; Davidoff
et al., 1991a; Marks et al., 1991).
However, in contrast to numerous papers on p53 overex-
pression in human cancer little is known about its role in
determining prognosis and reports from different groups are
inconsistent. Recently Scott et al. (1991) and Campo et al.
(1991) described the expression of p53 in colorectal cancer
but no correlation was found between p53 expression and the
most important clinico-pathological variables related to bio-
logical aggressiveness and stage of disease. This contrasts
with breast cancer where p53 expression has been related to
oestrogen, growth factor receptor status (Cattoretti et al.,
1988) and tumour stage (Davidoff et al., 1991a,b).
There is no published data on the frequency of expression
and prognostic significance of p53 protein in gastric cancer.
Previous reports on the expression ofp53 in colorectal cancer
have been limited to the use of frozen material as no suitable
reagents were available to detect p53 in routinely fixed,
paraffin embedded tissue. However, the recent availability of
the polyclonal antiserum CM 1 (D. Lane, personal com-
munication) has enabled studies to be performed on paraffin
material (Bartkova et al., 1991). The objective of the present
study was to investigate the value of immunohistochemical
detection of p53 protein in routinely fixed tissue as a prog-
nostic marker in colorectal and gastric carcinoma, using the
antiserum, CM1.
Material and methods
Clinical details
Fifty-five gastric and 107 colorectal carcinomas were included
in this study. Gastric specimens were obtained at endoscopy
or surgery performed in the Pomeranian Medical Academy,
Szczecin, Poland. The median age of the patients with gastric
cancer was 54.5 years (range, 24-70 years) and 65.4% of the
series was male. Twenty-two gastric tumours were located in
the antrum and pylorus region, 19 in the body, ten in the
cardia and fundus and in four patients, carcinoma affected
the whole stomach.
Among colorectal neoplasms examined there were 74 tu-
mours obtained at different Departments of Surgery in Man-
chester, UK and 33 tumours from the Medical Pomeranian
Academy, Szczecin, Poland. The median age of the patients
with colorectal carcinoma was 65.4 years (range, 22-80
years) and 66.3% of the series was male. Sixty-seven tumours
were located in the rectum, 15 in the sigmoid, six in the
descending colon, three in the transverse colon, seven in the
ascending colon and nine in the caecum. For further analysis
these were divided into rectal, and left or right sided colon
lesions. The macroscopic appearance was only assessed in
78/107 colorectal tumours; in ten cases the advanced disease
made categorisation difficult and in a further 19 this infor-
mation was unavailable. Forty-one of the colorectal tumours
were polyploid. The histological type and stage of tumour
were assessed from routine examination ofparaffin-embedded
sections stained with haematoxylin and eosin. There were 25
intestinal type, 28 diffused type and two mixed gastric car-
cinomas. Colorectal cancers were predominantly moderately
differentiated (70) or well differentiated (27), ten tumours
were poorly differentiated.
The stage groups were made for gastric cancer according
to the criteria of Japanese Research Society for gastric cancer
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and for colorectal carcinoma according to the criteria of
Dukes with modification by Turnbull et al. (Preece et al.,
1986; Fielding & Priestman, 1986). There were six, 12, nine
and 28 gastric cancers in stages I-IV respectively. The dist-
ribution ofcolorectal tumours was 13, 53, 27 and 14 in stages
A-D respectively. The histopathological diagnoses and
tumours localisation are shown in Tables II and III.
A follow-up of patients whose tumours were examined in
this study is currently in progress. The median survival of the
patients operated on for gastric cancer is 21 months (range,
9-54 months) and the median survival of patients with col-
orectal carcinoma is 12.1 months (range 9-26 months). Only
80/107 colorectal patients' follow-up data was analysed be-
cause six died of causes unrelated to cancer, 11 (disease free)
had too short a follow-up time and for ten cases the infor-
mation was unavailable.
Tissue preparation
One hundred and fifty-two biopsies were obtained at surgery
and ten at endoscopy (three gastric and seven colorectal
carcinomas). The tissue was fixed in 10% neutral formalin
and embedded in paraffin. In most of the cases, specimens
from the same patients were also immediately embedded in
OCT compound, frozen in liquid nitrogen and stored at
- 700C.
Immunohistochemistry
The polyclonal rabbit anti-p53 antibody, CM1, raised against
the full length human p53 protein (purified from bacteria
expressing the recombinant protein) was used for immunohis-
tochemistry. This antibody was kindly supplied by Dr David
Lane (CRC Dundee, UK). A three stage immunoperoxidase
technique was used. Briefly, the slides were incubated over-
night at 40C with polyclonal anti-p53 antibody, diluted 1/
1000 for frozen and 1/750 for paraffin material. The sections
were washed then treated consecutively for 30 min with
biotinylated swine anti-rabbit antibody (Dakopatts, A/s Den-
mark) diluted 1/400 in TBS and streptavidin HRP-conju-
gated reagent (Dako Ltd., UK) diluted 1/800, at room
temperature. Peroxidase was visualised using 0.05% solution
of diaminobenzidine tetrahydrochloride (DAB, Sigma) and
0.1% solution of nickel chloride in TBS containing 0.03%
hydrogen peroxide (10 min).
Finally, the slides were lightly stained in Mayer's haema-
lum. Replacement of the primary antibody with normal rab-
bit serum was used as a negative control. Colonic carcinomas
sections with high p53 expression were included in each
experiment to ensure that the procedure was working opti-
mally. Only tumours which exhibited intense nuclear staining
were categorised as p53 positive.
Sixty tumours (35 colorectal and 25 gastric carcinomas)
were tested on paraffin and frozen material.
Statistics
The p53 expression in gastric and colorectal carcinomas was
compared with prognostic clinical and histological features
and with follow-up data. Statistical analysis was done with
chi-square test and Fishers' Exact test, using significance level
of 0.05.
Results
The results of immunohistochemical evaluation are sum-
marised in Table I. p53 was detected in 26 out of 55 (47.3%)
gastric carcinomas and in 49 out of 107 (45.8%) colorectal
carcinomas. The p53 positivity rate for the colorectal car-
cinomas from the two centres was similar, 34/74 (45.9%) and
15/33 (45.6%) for English and Polish specimens respectively.
The immunoreaction was always localised in the nucleus of
neoplastic cells (Figure 1). The majority of p53 positive
colorectal and gastric neoplasms showed a uniform immuno-
TableI Gastricandcolorectaltissuesstainingwithanti-p53polyclonal
antibody, CMI
Histology Number examined p53 Positive n (%)
Stomach:
Adenocarcinoma 55 26 (47.3%)
Intestinal metaplasia 20 0
Atrophic gastritis 5 0
Non malignant epithelium 50 0
adjacent to carcinoma
Colon:
Adenocarcinoma 107 49 (45.8%)
Tubular and villous 20 0
adenoma
Non malignant epithelium 75 0
adjacent to carcinoma
staining through the carcinoma in all or nearly all malignant
cells. We systematically assessed intra-tumour heterogeneity
of p53 expression in three to five different areas of the same
tumour and no variation was found in seven cases of gastric
carcinoma and in five cases of colorectal cancer. Ten gastric
and two colorectal carcinomas revealed a focal positivity
with widely nonreactive areas. No cases with only occasional
positive cells were found. Uniform negative reactivity with
anti-p53 antibody was seen in normal epithelium adjacent to
carcinoma (n = 125), intestinal metaplasia (n = 20), atrophic
gastritis (n = 5) and in colonic adenomas (n = 20). There was
a good correlation between immunohistochemical staining on
paraffin and frozen material. Thus, no variations were found
in colorectal carcinoma for the 35 tumours tested but one of
the 25 gastric cancers tested was positive for p53 on the
frozen material and negative on the paraffin section.
The relationship between p53 expression and several clin-
ico-pathological criteria related to prognosis is shown in
Table II for gastric and Table III for colorectal carcinoma.
There is a highly significant correlation between p53 expres-
sion and tumour stage in gastric and colorectal carcinoma.
The proportion of positively reacting colorectal tumours in-
creases as the stage progresses (P<0.001). This increase is
also significant in gastric cancer when early stages (I and II)
are compared with stages III and IV (P<0.001). Also
tumours which had invaded regional lymph-nodes overex-
press p53 more frequently than localised carcinomas. Only
9% (two out of 23) gastric and 30% (20 out of 66) colorectal
tumours from the patients without metastases are p53 posi-
tive while 71% (20 out of 28) gastric and 63% (17 out of 27)
colorectal carcinomas with positive lymph-nodes overexpress
p53 protein (P<0.001 for gastric and P = 0.005 for colorec-
tal carcinoma).
p53 positivity in colorectal carcinoma correlates also with
macroscopic configuration and site of the primary tumour.
Ulcerative tumours are more frequently p53 positive than
polypoid (P<0.001) and carcinomas from the rectum ex-
pressed p53 more often than those from the left and the right
colon (P = 0.02). In gastric cancer p53 overexpression was
detected most frequently in tumours from the cardia but the
difference did not reach statistical significance (P = 0.27) and
was irrespective ofmacroscopic configuration. In both gastric
and colorectal carcinomas p53 expression was unrelated to
tumour grade, sex and age.
A follow-up of patients whose tumours were examined in
this study is currently in progress. Present results are shown
in Table IV. Statistical analysis of follow-up data of 47
patients with gastric carcinoma (20 with p53 positive and 27
with p53 negative tumours) and of 80 patients operated on
for colorectal cancer (36 with p53 positive and 44 with p53
negative tumours), revealed that p53 overexpression in both
carcinomas is significantly associated with early relapse and
death (P<0.001). Thus, 18 out of 20 (90%) patients who
had p53 positive gastric cancers and only six out of 27 (22%)
with negative tumours died during a 2 year period post
surgery. Similarly, in the group of patients with colorectal
cancer 25 out of 36 (69%) p53 positive and only five out of560 T. STARZYNSKA et al.
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Figure 1 Immunohistochemical detection of p53 protein in paraffin sections with anti-p53 polyclonal antibody CMI and a three
stage avidin-biotin-peroxidase technique ( x 400). a, Gastric carcinoma of intestinal type showing p53 labelling with intense nuclear
staining in the tumour cells with negative stromal cells; b, Gastric carcinoma of diffuse type showing nuclear positive staining and
c, control labelling of same tumour; d, A colorectal carcinoma showing p53 labelling of the tumour cells and negative staining in
the adjacent non-malignant tissue.
Table III p53 expression in colorectal carcinoma versus clinico-
pathological features related to prognosis
Table II p53 expression ingastriccarcinoma versusclinico-pathological
features related to prognosis
Clinico-pathologicalfinding
Sex: Male
Female
Age: < 50
>50
Macroscopic configuration:
Ulcer
Infiltrating
Tumour site:
Cardia and fundus
Body
Antrum and pylorus
All stomach
Histologic type:
Intestinal
Diffused
Mixed
Stage:
I
II
III
IV
Lymph-node:
Negative
Positive
aNot significant.
Number examined p53 positive
36 18 NSa
19 8
22 10 NS
33 16
19 9
36 17NS
10
19
22
4
25
28
2
{ 6
(12
9
28
7
8
10
1 NS
11
13
2 NS
(1 (11%)
(1
4 (44%)
20 (71%) P<0.001
23 2 (9%) P<0001
28 20 (71%)
Clinico-pathologicalfinding
Sex: Male
Female
Age: < 65
>65
Macroscopic configuration:b
Polyploid
Ulcerative
Stenosis
Tumour site:
Rectum
Left colon
Right colon
Histologic grade:
Poorly differentiated
Moderately differentiated
Well differentiated
Dukes' Stage:
A
B
C
D
Lymph-nodes:c
Negative
Positive
Number examined
71
36
58
49
41
33
4
67
(21
(19
10
70
27
13
53
27
14
p53 positive
32 NSa
27 NS
4 (10%) P<0001 22 (67%)
2
37 (55%) P<0.02
(5 (30%)
5
33 NS
3 (23%)
17 (32%)
17 (63%)
12 (86%) P<0.001
66 20 (30%) P<o.oos
27 17 (63%)
< 05
aNot significant. bOnly 78/107 because of difficulty of assigning
macroscopic configuration of the primary. cDoes not include distant
metastases.
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Table IV The correlation between p53 expression and follow-up
data
Follow-up
No. of Local Alive &
p53 expression cases Died recurrence well
Gastric cancer,a
2 years observation
p53 + 20 18 2
p53- 27 6 - 21
Colorectal cancer,a
I year observation
p53+ 36 18 7 11
p53- 44 4 1 39
ap<o.ooi.
44 (11%) p53 negative patients developed local recurrence or
died during the first year post surgery.
Discussion
The novel and principle finding of this study is that in gastric
and colorectal cancers the expression of the p53 protein
correlates with established prognostic factors. Furthermore,
good correlation was found between immunohistochemical
staining on paraffin and frozen sections which is important
for routine pathology and clinical practice. Using the poly-
clonal antiserum, CM1, on routinely fixed, paraffin embed-
ded tissue, p53 was detected in 47% gastric and in 46%
colorectal carcinomas and was undetectable in intestinal
metaplasia, atrophic gastritis, colonic adenomas and normal
epithelium adjacent to carcinoma. These results are the first
to describe p53 expression in gastric cancer and confirm the
high frequency of p53 overexpression in colorectal cancer
and negative p53 immunostaining in nonmalignant tissue
(Crawford et al., 1984; Remvikos et al., 1990; Rodrigues et
al., 1990; Scott et al., 1991; Campo et al., 1991).
In considering the prognosis of patients with gastric and
colorectal carcinoma there are a number of clinical and
pathological variables which relate to survival. The most
important is stage of disease. In this study, the correlation
between p53 expression and stage of gastric and colorectal
tumours is very significant. Only 9% gastric and 30% col-
orectal cancers with localised disease expressed high levels of
p53 protein whereas 71% gastric and 63% colorectal
tumours which had invaded regional lymph-nodes overex-
pressed p53. Furthermore, the proportion of positively reac-
ting tumours increased as the stage progressed.
The site of the primary tumour in stomach and large bowel
has been found to have an influence on spread and survival
(Fielding & Priestman, 1986; Preece et al., 1986). The prog-
nosis is worse for cancers which originate in the upper third
of stomach or in the rectum. It also has been demonstrated
that colorectal carcinomas of the fungating type metastasised
less frequently than ulcerative tumours (Fielding & Priest-
man, 1986). In our study p53 overexpression in colorectal
cancer was most frequently detected in tumours from the
rectum and in ulcerative carcinomas. In gastric cancer, tu-
mours from the cardia were more often p53 positive than
those from the body and pylorus, but the differences did not
reach statistical significance. Another prognostic indicator is
tumour grade, but in our series p53 overexpression was
irrespective of tumour grade.
Analysis of present follow-up data revealed that p53
overexpression is significantly associated with early relapse
and death. Ninety per cent of patients with gastric car-
cinoma, who had p53 positive tumours died during a 2 year
period post surgery compared to 22% of those with p53
negative tumours. Similarly, in the group of patients oper-
ated on for colorectal cancer 69% of p53 positive and only
11% of p53 negative patients developed local recurrence or
died during the first year post surgery. In conclusion, our
results show that p53 overexpression in gastric and colorectal
carcinoma correlates with poor prognosis.
There is no published data on the prognostic significance
of p53 protein in gastric cancer and little is known about its
role in determining prognosis in colorectal carcinoma. Rem-
vikos et al. (1990), investigated 41 colorectal tumours and
found a significant association between elevated p53 and the
presence of DNA aneuploidy, a factor connected with poor
prognosis but not with Dukes stage. They suggested that
evaluating p53 expression may prove useful in determining
different biological subgroups of colorectal cancer. However,
in a later study of 52 colorectal carcinomas (Scott et al.,
1991), no correlation was observed with p53 overexpression
and several variables related to prognosis such as Dukes
stage, tumour grade, presence of aneuploidy and patient
survival with the exception of tumour site. Recently, Campo
et al. (1991) also did not find a relationship between p53
expression and degree of differentiation, the stage of the
tumour or the Ki-67 proliferation index in 64 colorectal
carcinomas. These authors concluded that p53 could not be
used as a prognostic indicator in colorectal cancer.
The differences between our findings and previous studies
on the role of p53 expression in determining prognosis might
reflect differences in the number of tumours examined or the
different kind of material, methods and antibodies used. One
hundred and seven colorectal carcinomas were included in
this study and p53 detected immunohistochemically on
paraffin embedded tissue with a polyclonal antiserum and an
overnight incubation step. Scott et al. (1991) and Campo et
al. (1991) studied significantly lower numbers of tumours (52
and 64 respectively), used frozen material, monoclonal anti-
bodies and short incubation times. Furthermore Scott et al.
(1991) used only one monoclonal antibody Pab 421 which
recognises an epitope between amino acids 370 and 378 of
p53. Absence of this epitope may be of significance as the use
of Pab 421 antibody alone might lead to underestimation of
the number of tumours overexpressing p53 (Arai et al., 1986;
Bartek et al. (1990a) and can affect final results on the
relationship between p53 expression and prognostic factors.
Remvikos et al. (1990) also studied lower numbers of car-
cinomas (41) and used flow cytometry, so occurrence of some
p53 loss during tissue processing could not be excluded.
However the proportions of p53 overexpressing colorectal
tumours in this study and those of Scott et al. and Campo et
al. are not that different.
Our findings of an increased percentage ofp53 positivity in
rectal versus right sided tumours and of irrespectivity of p53
expression in relation to tumour grade are consistent with
other studies on colorectal carcinoma. Scott et al. (1991) and
Campo et al. (1991) demonstrated that right sided tumours
were less p53 immunoreactive than distal carcinomas and did
not find a correlation between p53 expression and tumour
differentiation. Our data are also consistent with recent
studies on breast cancer which also reported a prognostic
significance of p53 overexpression. Davidoff et al. (199la,b)
demonstrated that frequency of p53 overexpression in breast
cancer was related to stage of disease and might provide
prognostic information. In a large study Cattoretti et al.
(1988) also showed that p53 in mammary carcinomas was
associated with oestrogen receptor-negative, growth factor
receptor-positive and high grade tumours, known indicators
of poor prognosis. The results reported in this paper suggest
that in gastric and colorectal carcinoma alterations in p53
expression are rather late events, significantly associated with
advanced stage of disease, early relapse and death. Our data
also show that the polyclonal antiserum CM1 detects ele-
vated levels of p53 protein equally well in formalin fixed,
paraffin embedded or frozen material. The implication of
these findings is that, immunohistochemical detection of p53
can be a valuable tool in routine pathology for p53 screening
in gastric and colorectal cancer, to identify, along with other
established prognostic factors, patients with poor short-term
prognosis and to decide on optimal treatment for this group.
We found that p53 overexpression is related to a poor prog-
nosis, but our follow-up time does not allow conclusions on
p53 negative cases. Further long-term follow-up is necessary562 T. STARZYNSKA et al.
to determine whether p53 immunostaining may delineate
subsets of gastric and colorectal tumours having particular
biological and clinical behaviour. Such studies are currently
in progress.
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